A series of recent decisions show that the Indian courts have fully come to terms with the demands of patent litigation, says Vidisha Garg.
January 1, 2005 was a crucial milestone in the history of India’s patent system as it marked the end of the transition period granted by TRIPS to comply with its provisions on pharmaceutical product patents. Since then, India has introduced a revolutionary and promising regime, popularly known as the ‘product patent regime’.
Under this regime, India has opened its doors to product patents for food, chemicals and pharmaceuticals. Now, pharmaceutical companies can obtain full-scale patent protection on their products and prevent local companies from manufacturing generic versions of their patented products.
While the new patent regime offered a host of new opportunities to multinationals and innovator companies, it became a major issue of concern for the generic pharmaceutical industry in India. The provisions of pre-grant and postgrant oppositions led to a drastic change in the patent prosecution pattern. Patent offices were flooded with an unprecedented number of oppositions against the patents/applications of innovator pharmaceutical companies. Some of the patents faced multiple challenges.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email tech support.
India IP law, amendments, TRIPS, pharmaceuticals